[1] W. Sauerweina,The EORTC Boron Neutron Capture Therapy (BNCT) Group: achievements and future projects European Journal of Cancer 38 , S31–S34,2002.

[2] M. Timonen et al. Spectrosc-Int J 18,133,2004.

[3] A. Valda,Development of a Tomographic System for Online Dose Measurements in BNCT (Boron Neutron Capture Therapy) Brazilian Journal of Physics, vol. 35, no. 3B, September, 2005

[4] W. Verbakel, F. Stecher-Rasmussen, Nucl. Instr. and Meth. A 394 ,163,1997.

[5] Laakso J: Atomic emission method for total boron in blood during neutron-capture therapy. Clin Chem 47: 1796–1803, 2001

[6] Barth RF, Adams DM, Soloway AH, Mechetner EB, Alam F, Anisuzzaman AK. Determination of boron in tissues and cells using direct-current plasma atomic emission spectroscopy. Anal Chem;63:890–3,1991.

[7] Smith D R, Chandra S, Coderre J A and Morrison G H Cancer Res. 56 4302–6,1996.

[8] Ceberg C P. Radiother. Oncol. 26 139–46,1993.

[9] H. Yanagië, H. Kobayashi, “Neutron capture autoradiographic determination of 10B distributions and concentrations in biological samples for boron neutron capture therapy”, Nucl. Instr. Meth., A 424, , pp.122-128,1999.

[10] Johansson, S.A.E. Particle-Induced X-ray Emission Spectrometry (PIXE), in Chemical Analysis. Vol. 133, Wiley, New York. 1995.

[11] Kabalka GW, Nichols TL, Smith GT, Miller LF, Khan MK: The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma. J Neuro-Oncol 62: 187–195, 2003.

[12] Bendel P, Koudinova N and Salomon Y, In vivo imaging of the neutron capture therapy agent BSH in mice using 10BMRI Magn. Reson. Med. 46 13–7,2001a.

[13] Zuo CS, Prasad PV, Busse P, Tang L, Zamenhof RG: Proton nuclear magnetic resonance measurement of p-boronophenylalanine (BPA): a therapeutic agent for boron neutron capture therapy. Med Phys 26: 1230–1236, 1999.